← Back to Screener
Palisade Bio, Inc. Common Stock (PALI)
Price$2.33
Favorite Metrics
Price vs S&P 500 (26W)13.01%
Price vs S&P 500 (4W)12.96%
Market Capitalization$388.17M
All Metrics
Book Value / Share (Quarterly)$0.81
P/TBV (Annual)1.58x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-3.07%
Net Profit Margin (TTM)-936.00%
EPS (TTM)$-4.92
10-Day Avg Trading Volume3.69M
EPS Excl Extra (TTM)$-4.92
EPS (Annual)$-10.19
ROI (Annual)-190.70%
Net Profit Margin (5Y Avg)-37513.22%
Cash / Share (Quarterly)$0.84
ROA (Last FY)-132.70%
EBITD / Share (TTM)$-3.57
ROE (5Y Avg)-188.72%
Operating Margin (TTM)-1011.60%
Cash Flow / Share (Annual)$-0.07
P/B Ratio3.00x
P/B Ratio (Quarterly)2.71x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)1019.43x
Net Interest Coverage (TTM)-1202.17x
ROA (TTM)-135.09%
EPS Incl Extra (Annual)$-10.19
Current Ratio (Annual)28.95x
Quick Ratio (Quarterly)28.83x
3-Month Avg Trading Volume4.64M
52-Week Price Return234.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1896.75
P/S Ratio (Annual)1552.68x
Asset Turnover (Annual)0.02x
52-Week High$2.64
Operating Margin (5Y Avg)-29730.27%
EPS Excl Extra (Annual)$-10.19
Tangible BV CAGR (5Y)20.01%
26-Week Price Return17.00%
Quick Ratio (Annual)28.83x
13-Week Price Return23.16%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)28.95x
Enterprise Value$254.856
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-79.85%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4920.00%
Cash / Share (Annual)$0.84
3-Month Return Std Dev87.92%
Net Income / Employee (TTM)$-1
ROE (Last FY)-192.71%
Net Interest Coverage (Annual)-986.08x
EPS Basic Excl Extra (Annual)$-10.19
Receivables Turnover (TTM)0.20x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.92
Receivables Turnover (Annual)0.20x
ROI (TTM)-208.92%
P/S Ratio (TTM)1552.68x
Pretax Margin (5Y Avg)-37513.22%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2405.25
Price vs S&P 500 (52W)204.46%
Year-to-Date Return-0.43%
5-Day Price Return18.18%
EPS Normalized (Annual)$-10.19
ROA (5Y Avg)-129.62%
Net Profit Margin (Annual)-4920.00%
Month-to-Date Return33.71%
Cash Flow / Share (TTM)$-2.62
EBITD / Share (Annual)$-10.18
Operating Margin (Annual)-5228.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-187.02%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.92
P/TBV (Quarterly)3.88x
P/B Ratio (Annual)2.71x
Pretax Margin (TTM)-936.00%
Book Value / Share (Annual)$0.81
Price vs S&P 500 (13W)22.47%
Beta1.54x
Revenue / Share (TTM)$0.00
ROE (TTM)-214.87%
52-Week Low$0.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.17
4.23
4.21
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PALIPalisade Bio, Inc. Common Stock | 1552.68x | — | — | — | $2.33 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Palisade Bio is a clinical-stage biopharmaceutical company developing therapeutics to protect intestinal barrier function. Its lead candidate, PALI-2108, targets inflammatory bowel disease, including ulcerative colitis and Crohn's disease, while PALI-1908 is in early-stage research. The company is positioned in the gastrointestinal immunology market.